Trial Profile
A Randomized, Controlled, Open-label Study Evaluating the Efficacy and Tolerability of AMG 531 Versus Medical Standard of Care as Chronic Therapy for Non-splenectomized Subjects With Immune (Idiopathic) Thrombocytopenic Purpura
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Romiplostim (Primary)
- Indications Thrombocytopenic purpura
- Focus Therapeutic Use
- Sponsors Amgen
- 01 Jun 2020 Results of integrated analysis of five clinical trials evaluating the efficacy and safety of romiplostim self-administration published in the American Journal of Hematology
- 18 Nov 2014 New trial record